– Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 – – Announced positive 30-day data from the Company’s ongoing U.S. Investigational Device Exemption (IDE) clinical trial, C-GUARDIANS, designed to support U.S. approval of CGuard Prime – – Named Patrick Geraghty, M.D. and […]
Author: Ken Dropiewski
LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029
LONDON–(BUSINESS WIRE)– #cardiacsurgery–LivaNova announced the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 issued in a private offering.
Merit Medical to Host Evening of Innovation during the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting
SOUTH JORDAN, Utah, March 05, 2024 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today a series of events for clinicians attending the 2024 SIR Annual Meeting. These educational events will take place at Merit’s headquarters and at SIR booth 320. On […]
Cleerly® Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System
DENVER–(BUSINESS WIRE)–Cleerly, the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its Coronary Artery Disease (CAD) Staging System. The CAD Staging System is a […]
Cardio Diagnostics Holdings, Inc. Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announces that the U.S. Patent and Trademark Office has issued a notice of allowance to University of Iowa Research Foundation (“UIRF”) for U.S. Application No. 17,857,723 titled Compositions and Methods for Detecting Predisposition to Cardiovascular Disease, which is […]
Endologix Appoints Mike Mathias as Chief Commercial Officer
IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced the appointment of Mike Mathias as the company’s Chief Commercial Officer, effective immediately. With a distinguished 30-year career in leading commercial organizations within the cardiovascular arena, […]
Associated Medical Professionals of NY Revolutionizes Men’s Health Care with Groundbreaking New IR Center and BPH Treatment Initiative
SYRACUSE, N.Y.–(BUSINESS WIRE)–U.S. Urology Partners affiliate Associated Medical Professionals of NY launches innovative BPH initiative, outpatient Interventional Radiology Center
LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes
LONDON–(BUSINESS WIRE)– #cardiacsurgery–LivaNova PLC announced its intention to offer $300 million aggregate principal amount of convertible senior notes due 2029 in a private offering.
Stereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States
ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that regulatory submissions were made recently in both Europe and the United States for the MAGiC™ catheter. These submissions follow successful initial clinical results […]
Stereotaxis Reports 2023 Full Year Financial Results
ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2023. “We enter 2024 having made significant progress in realizing our strategic […]



